A Phase I Open-label Study of Selinexor with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers

PURPOSE: Selinexor, a selective inhibitor of nuclear export, monotherapy causes nuclear accumulation of tumor-suppressor proteins and has anti-tumor activity in ovarian and endometrial cancers. The safety and tolerability of oral selinexor plus intravenous carboplatin and paclitaxel chemotherapy (se...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Rubinstein, Maria M., Grisham, Rachel N., Cadoo, Karen, Kyi, Chrisann, Tew, William P., Friedman, Claire F., O’Cearbhaill, Roisin E., Zamarin, Dmitriy, Zhou, Qin, Iasonos, Alexia, Nikolovski, Ines, Xu, Hongmei, Soldan, Krysten N., Caird, Imogen, Martin, Madhuri, Guillen, Joyce, Eid, Khalil T., Aghajanian, Carol, Makker, Vicky
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779742/
https://ncbi.nlm.nih.gov/pubmed/33139041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.10.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados